Janus kinase (JAK) Inhibitors are the latest drug class of disease-modifying medication to
emerge for the treatment of rheumatoid arthritis (RA). They are a small molecule-targeted …

Profound and debilitating fatigue is the most common complaint reported among individuals
with autoimmune disease, such as systemic lupus erythematosus, multiple sclerosis, type 1 …

Rheumatoid arthritis is a common chronic inflammatory disorder and a major cause of
disability. Despite the progress made with recent clinical use of anti-cytokine biologics, the …

Tofacitinib and baricitinib are the first orally available, small-molecule inhibitors of Janus
kinase (JAK) enzymes to be approved for the treatment of RA. Tofacitinib is a selective JAK1 …

Context The impact of various dietary interventions on rheumatoid arthritis (RA),
characterized by immune-inflammatory response, has been subject to increased attention …

The failure rate for the translation of drugs from animal testing to human treatments remains
at over 92%, where it has been for the past few decades. The majority of these failures are …

Accumulating research evidence suggests that nutrition might be implicated in the risk of
development and in the management of autoimmune disease, including rheumatoid arthritis …

The biological DMARD (bDMARD) abatacept (Orencia®), a recombinant fusion protein,
selectively modulates a co-stimulatory signal necessary for T-cell activation. In the EU …

Sustained clinical remission (CR) without drug treatment has not been achieved in patients
with rheumatoid arthritis (RA). This implies a substantial difference between CR and the …

Fatigue in rheumatoid arthritis is highly prevalent. It is correlated only weakly with disease
activity but more so with pain, mood, personality features, poor sleep, obesity and …